Analysis of the Survival of Patients With Breast Cancer Depending on Age, Molecular Subtype of Tumor and Metabolic Syndrome

Abstract

Aim: To analyze the survival of patients with breast cancer (BC) depending on age, molecular subtype of the tumor and the presence of metabolic syndrome. Patients and Methods: We have analyzed the results of examination and treatment of 202 patients with BC of stages I–III. The patients were distributed by age into 2 groups. The group 1 included 86 elderly patients (from 65 to 84 years old), the group 2 — 116 younger patients (from 32 to 64 years). An overall 1-, 3- and 5-year survival rates of the treated patients were assessed. The significance of factors influencing the overall survival (OS) of patients with BC was determined using the methods of statistical analysis. Results: Molecular subtype of BC significantly affects survival rates: in a case of a luminal B subtype the 5-year OS was 71.6% vs 80% (p < 0.05) in groups 1 and 2, respectively while in a case of a basal-like subtype it was 60.2% and 71.6% (p < 0.05). The presence of metabolic syndrome significantly reduced the 5-year OS (up to 70.7% and 80.6%, p < 0.05 in groups 1 and 2, respectively). Conclusion: The OS is lower in elderly patients with BC compared with younger patients, especially in those who suffer from metabolic syndrome.

Association between metabolic syndrome and prognosis of breast cancer: a meta-analysis of follow-up studies

“…For the remaining 29 potential relevant studies that underwent full text review, 20 were further excluded because eight of them were not cohort studies, two did not include MetS as exposure of interest, eight included patients without breast cancer at baseline, and the other two were repeated abstracts of the included studies. Finally, nine follow-up studies were included [15][16][17][18][19][20][21][22][23]. Li et al Diabetol Metab Syndr (2020) 12:10…”

“…Overall, this meta-analysis included nine cohort studies [15][16][17][18][19][20][21][22][23] with 17,892 women with breast cancer. Since three studies provided data based on the status of hormone receptors (HR) of the cancer [16,19,20] and one study based on age stratification [22], these datasets were included separately. The characteristics of the included cohorts were shown in Table 1.…”

“…The characteristics of the included cohorts were shown in Table 1. Three of them were prospective cohort studies [15,18,19], while the other six were retrospective cohort studies [16,17,[20][21][22][23]. All of these studies included breast cancer women who received anti-cancer therapy and were with no signs of recurrence at baseline.…”

The prognostic link between metabolic syndrome and the different breast cancer molecular subtypes: a case control study.

“…Epidemiological studies have indicated the close association between MetS and increased risk of recurrence and overall mortality due to BC (7,9,10). Based on the intrinsic molecular subtypes, some researchers reported that a non-significant trend for increased risk of mortality was observed among the hormone-receptor (HR)positive patients with BC and MetS (11,12). Moreover, the lack of data on Her-2 status may affect the conclusion of the impression of Mets on the prognosis of early BC, which is based on the molecular profiles.…”

“…Moreover, the lack of data on Her-2 status may affect the conclusion of the impression of Mets on the prognosis of early BC, which is based on the molecular profiles. Accordingly, several related studies have shown conflicting results because of the hypothesis that the different components of MetS may be involved in the development and prognosis of the molecular subtypes of BC (11)(12)(13)(14).…”